Metabolon To Identify Disease Biomarkers For CDC Multiple Sclerosis Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 26, 2005--Metabolon, Inc., a leader in the discovery of biomarkers using metabolomics, today announced it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to identify disease biomarkers for multiple sclerosis.
MORE ON THIS TOPIC